5Y News | PAM2L Biotechnologies Closes Tens of Millions of RMB in Angel+ Round
Opening a new paradigm in synthetic biomaterials R&D.
PAM2L Biotechnologies, a company focused on the R&D and application of innovative biomaterials, announced today that it has raised tens of millions of RMB in an angel+ round. Tiantu Capital led the round, with Cornerstone Capital participating. The proceeds will be used primarily to expand the company's R&D center and build a pilot-scale production platform.
Founded in 2021 by Dr. Chao Zhong, a researcher at the Shenzhen Institute of Advanced Technology (SIAT) of the Chinese Academy of Sciences and recipient of the National Science Fund for Distinguished Young Scholars, PAM2L is driven by a dual-core technology engine combining synthetic biology and machine learning (BT-IT). The company is dedicated to developing bio-based materials and related products, providing customers with safe, efficient, and green solutions. Its core product pipeline currently focuses on protein and polysaccharide materials, with applications spanning pharmaceuticals, cosmetics, and food.
In December 2021, PAM2L had just raised nearly $5 million in an angel round from 5Y Capital. The company previously received certification as a "synthetic biology enterprise" from Guangming District, Shenzhen — the first district-level government in China to issue a dedicated local synthetic biology policy. PAM2L also serves as a flagship example of the "upstairs-downstairs innovation complex" model pioneered by SIAT Shenzhen, where research institutes sit upstairs and companies operate downstairs.
5Y Capital seeks out, supports, and inspires founders who are going it alone, providing them with support from the spiritual to the operational. We believe that if the you whom others see as crazy starts to be believed in, the world will become a different place.
BEIJING · SHANGHAI · SHENZHEN · HONG KONG
